Akkermansia-Lactobacillus Probiotic Composition for Hypertension Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hypertension treatments rely heavily on medications that can cause side effects and lead to dependence, necessitating safer alternatives.
Innovation Solution
A probiotic preparation combining Akkermansia muciniphila Akk11 and Lactobacillus rhamnosus LRa05 strains, formulated to synergistically enhance blood pressure regulation, renal function, and oxidative stress response, offering a safer and effective treatment for hypertension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional hypertension medications (ACE inhibitors and calcium channel blockers) are used for long-term treatment, then blood pressure control is achieved, but side effects and patient dependence increase
Solution Approach 1:
The patent combines two probiotic strains (Akkermansia muciniphila and Lactobacillus rhamnosus) into a single preparation to achieve synergistic anti-hypertensive effects. This merging of multiple beneficial microorganisms enhances therapeutic efficacy while avoiding the harmful side effects associated with traditional pharmaceutical interventions.
Solution Approach 2:
The patent employs probiotic organisms that are biologically active but transient in their action mechanism, replacing long-term pharmaceutical dependence with temporary probiotic intervention that resets physiological balance without creating dependency.
2Object-affected harmful factors
If probiotic preparations are developed as alternatives to traditional medications, then safety and reduced dependence are achieved, but treatment efficacy may be insufficient
Solution Approach 1:
The patent creates a composite probiotic preparation containing two different bacterial strains (Akkermansia muciniphila and Lactobacillus rhamnosus) that work synergistically. This composite approach combines the beneficial effects of each strain to achieve enhanced anti-hypertensive efficacy while maintaining the safety advantages of probiotic-based therapy.
Solution Approach 2:
The patent leverages the dynamic interaction between two probiotic strains that complement each other's mechanisms of action, creating a flexible and adaptive therapeutic system that can effectively address hypertension through multiple physiological pathways simultaneously.
3Device complexity
If single-strain probiotic preparations are used, then simplicity and safety are maintained, but synergistic efficacy is not achieved
Solution Approach 1:
The patent merges two probiotic strains into a single integrated preparation, achieving synergistic blood pressure regulation effects that exceed the sum of individual strain effects, while maintaining practical simplicity in formulation and administration.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a probiotic preparation containing an Akkermansia muciniphila Akk11 strain for alleviating hypertension, and the probiotic preparation includes an Akkermansia muciniphila Akk11 strain and a Lactobacillus rhamnosus LRa05 strain, which are found to have potential interactions between the two, and to be able to complement each other in terms of their efficacy in alleviating hypertension synergistically; specifically manifested in: significantly enhancing the ability of blood pressure regulation, and optimizing the mechanism of blood pressure regulation; significantly regulating the levels of urinary protein and serum creatinine, which are markers of renal function, effectively alleviating renal function, and alleviating renal damage caused by hypertension; and significantly optimizing the response to oxidative stress, and enhancing the antioxidant defense ability of the body.